Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808442 · ClinicalTrials.gov registry record · Phase 1
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
A Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT02808442: Completed Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia, sponsored by Institut de Recherches Internationales Servier.
NCT02808442 is a Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808442, a Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Primary Outcome
Adverse events assessed according to NCI-CTCAE v5.0 criteria
Conditions Studied
Interventions
- BIOLOGICAL UCART19
Study Locations (6)
Other
- Hôpital Robert-Debré - Paris
- Hospital San Juan De Dios - Barcelona
- UCL Great Ormond Hospital - London
California
- Children's Hospital Los Angeles - Los Angeles
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2020-11-04 |
| Phase | Phase 1 |
What the finished NCT02808442 record still lists
NCT02808442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Relapsed B-Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which UCART19 is the first listed.
NCT02808442 lists 6 locations in 4 states (Other, California, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02808442 about?
NCT02808442 is a clinical study titled "Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia". This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
What is the current status of trial NCT02808442?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2016-06-03. Estimated completion is 2020-11-04.
What conditions does trial NCT02808442 study?
This clinical trial studies the following conditions: Relapsed B-Cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT02808442?
The interventions under investigation include: UCART19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02808442?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808442 being conducted?
This trial has 6 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed B-Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02808442's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI